

**Press release**

**REORGANISATION OF GOVERNANCE AND OPTIMISATION OF THE MANAGEMENT STRUCTURE TO BOOST COMMERCIAL GROWTH THROUGH TARGETED STRATEGIES AND PLANNING:**

**OTOFARMA APPOINTS GENNARO BARTOLOMUCCI AS ITS NEW CHIEF EXECUTIVE OFFICER, THUS ACCELERATING THE IMPLEMENTATION OF THE OVERALL CORPORATE CONVERGENCE PLAN**

*Naples, 23 March 2026* – **Otofarma** – a leading group in the production of hearing aids distributed mainly through the pharmaceutical channel, with over 30 years of experience in the hearing care sector – announces a reorganisation of the governance structure, involving a review of the allocation of powers within the Board of Directors and the appointment of Gennaro Bartolomucci, Chairman of the Board, as the Company's new Chief Executive Officer.

This reorganisation of the corporate governance structure represents a key strategic step for the Group: as the Company's founder and an expert in the business model and market dynamics, the new Chief Executive Officer, who will continue to serve as Commercial Director, takes the strategic helm of the Company with the aim of accelerating the implementation of the business plan and enhancing the main areas of development, with particular reference to the Otofarma 2.0 General Corporate Convergence Plan.

*"This reorganisation of the governance structure represents a natural step in Otofarma's growth journey,"* said Gennaro Bartolomucci. *"The Otofarma 2.0 General Business Convergence Plan, which provides for a structured organisation of the entire sales network with the Area Manager at its core, is a fundamental strategic lever for the Company's future and, at this stage, requires direct oversight and accelerated implementation."*

The central role of the 2.0 Convergence Plan in the Company's development – which aims to fully capitalise on market opportunities and generate sustainable value for shareholders and partners – is what, together with the overhaul of corporate governance, has also necessitated an optimisation of the management structure and management control, and consequently the assignment of new responsibilities to Giovanna Incarnato Bartolomucci.

Indeed, Ms Incarnato Bartolomucci will continue to serve as a Director; however, drawing on the professional experience she has gained over more than 25 years at the helm of Otofarma SpA and its subsidiaries, she will take on the role of Chief Operating Officer (COO), with responsibility for supervising and managing internal processes, production and human resources, in order to translate the company's strategic plan into concrete results and ensure soundness, consistency and compliance in its implementation.

The Board of Directors and the Chairman formally thanked Ms Giovanna Incarnato Bartolomucci for the excellent work she has carried out over the years, thanks to which the company has reached the significant milestone of being listed on the stock exchange.

*"I would like to express my full satisfaction with the progress made by the Otofarma Group in recent years and with the results achieved, which provide a solid foundation for the challenges ahead,"* said Giovanna Incarnato Bartolomucci. *"Handing over the reins to Dr Gennaro Bartolomucci means strategic continuity for Otofarma and an acceleration in the development of key projects; for me, in my role as COO, as well as a Director, it means being able to focus my skills and commitment fully on management and control activities, which are fundamental to the Company's growth."*

Following the Group's corporate reorganisation in the months leading up to the listing and given that 2025 is the first financial year for which the Company is required to prepare consolidated financial statements, it has been necessary to postpone the approval of the financial results. Consequently, during the Board of Directors' meeting, amendments to the calendar of corporate events were approved; the updated calendar is as follows:

Date	Event
28th of May 2026	Board of Directors' meeting to approve the draft annual financial statements and the consolidated financial statements as of 31 December 2025
25th of June 2026	Ordinary General Meeting of Shareholders to approve the Company Financial Statements and take note of the Consolidated Financial Statements as of 31 December 2025
29 September 2026	Board of Directors meeting to approve the consolidated half-yearly financial report as at 30 June 2026, voluntarily subject to a limited audit

\*\*\*

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website [www.otofarmaspa.com](http://www.otofarmaspa.com).

### **Identification Codes**

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

\*\*\*

### **About Otofarma SpA**

*Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.*

*Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.*

*Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.*

### **For more information:**

#### **Otofarma S.p.A.- Investor relations**

Anna Incarnato Bartolomucci

E-mail: [investor.relations@otofarma.it](mailto:investor.relations@otofarma.it)

mob: +39 347 0506780

#### **Alantra – Euronext Growth Advisor**

E-mail: [ega@alantra.com](mailto:ega@alantra.com)

mob: +39 334 6267242

#### **SEC Newgate – Media Relations**

+39 02 624 999 1

Michele Bon – [michele.bon@secnewgate.it](mailto:michele.bon@secnewgate.it) – +39 338 693 3868

Francesca Brambilla – [francesca.brambilla@secnewgate.it](mailto:francesca.brambilla@secnewgate.it) – +39 338 627 2146